FIELD: pharmaceuticals.
SUBSTANCE: invention relates to a compound of the following formula
, where R is selected from the group consisting of
and 
; X is CH or N; R1 is hydrogen or fluorine; and R2 is C1-C3 alkyl; or to its pharmaceutically acceptable salt. The invention also relates to a pharmaceutical composition having PERK inhibitor activity based on the said compound.
EFFECT: obtaining new compounds and a pharmaceutical composition based on them which can be used in medicine as effective agents for the treatment of prostate cancer.
11 cl, 4 tbl, 9 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMPOUNDS AND COMPOSITIONS FOR SUPPRESSING SHP2 ACTIVITY | 2017 |
|
RU2744988C2 |
| HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS | 2018 |
|
RU2797822C2 |
| COMPOUNDS OF 1-CYANO-PYRROLIDINES AS USP30 INHIBITORS | 2016 |
|
RU2717238C2 |
| HETEROCYCLIC COMPOUNDS USEFUL AS PDK1 INHIBITORS | 2010 |
|
RU2615130C2 |
| XIA FACTOR INHIBITORS | 2016 |
|
RU2728783C2 |
| TREATMENT METHOD | 2012 |
|
RU2621148C2 |
| NEW SUBSTITUTED BIARYL COMPOUNDS AS INDOLAMINE-2,3-DIOXYGENASE (IDO) INHIBITORS | 2018 |
|
RU2786586C2 |
| COMPOSITIONS FOR PREVENTION OR TREATMENT OF UVEITIS | 2019 |
|
RU2757273C1 |
| DERIVATIVES OF ARYLSULPHONYLSTILBENE FOR TREATMENT OF INSOMNIA AND ASSOCIATED WITH IT DISORDERS | 2005 |
|
RU2382766C2 |
| COMPOUNDS AND METHODS FOR ENHANCED DEGRADATION OF TARGET PROTEINS AND OTHER POLYPEPTIDES BY AN E3 UBIQUITIN LIGASE | 2013 |
|
RU2666530C2 |
